DV

Alliance Pharma PLCMUN Alliance Pharma Stock Report

Last reporting period 30 Jun, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

0.023

Micro

Exchange

XMUN - Boerse Muenchen

DVL.MU Stock Analysis

DV

Uncovered

Alliance Pharma PLC is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-2/100

Low score

Market cap $B

0.023

Dividend yield

3.28 %

Shares outstanding

540 B

Alliance Pharma Plc is a holding company, which engages in the acquisition, marketing, and distribution of healthcare and pharmaceutical products. The company is headquartered in Chippenham, Wiltshire and currently employs 250 full-time employees. The company went IPO on 2001-11-22. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. The firm's asset portfolio focused on two areas: Consumer Healthcare brands and Prescription Medicines. The company holds marketing rights to approximately 80 consumer healthcare brands and Prescription Medicines, which are sold worldwide in approximately 100 countries. Its products include Aloclair, Alliance Calcium Syrup, Aiweidi, Biodermatin, Biotaches, Changmin, Decapional, Dermachronic, Dermacide, Dervida, Effadiane, Fazol, Flammacerium, Gen-Ongles, Irenat, Malunjunshe, MolluDab, Neostigmine and Nu-Seals and other. The Company’s brands also include Kelo-Cote, Nizoral, Amberen, MacuShield, Vamousse, Hydromol, Forceval, Ashton & Parsons, Anbesol, and Aloclair. Its geographical area includes Europe, Middle East and Africa (EMEA), Asia Pacific and China (APAC) and Americas (AMER).

View Section: Eyestock Rating